Small molecule · Inhibitor of Enhancer of zeste homolog 2 (EZH2) · developed by Novartis Pharmaceuticals
Tulmimetostat is an orally available inhibitor of the histone methyltransferase EZH2, the catalytic subunit of polycomb repressive complex 2, and also acts on EZH1. It blocks methylation of histone H3 at lysine 27, altering gene expression in cancer cells. It is being studied in metastatic hormone-sensitive prostate cancer, in combination with darolutamide or abiraterone.
Summary written with AI from the sources listed at the end of this page.
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →